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Introduction. A skin-sparing or nipple-sparing mastectomy is a surgical treatment that is increasingly used in the treatment 
of patients with breast cancer. More often women themselves decide or even ask to undergo this type of surgery. In our 
paper, we present the issue of combined treatment of 62 patients after nipple-sparing or skin-sparing mastectomy with 
a positive sentinel lymph node. Realisation of this type of surgery has further consequences in adjuvant treatment policies.
Material and methods. The group of 62 previously untreated women with positive sentinel lymph nodes took part in 
this analysis. The individual plan of treatment was established for every patient by the multidisciplinary team according 
to the rules of the breast cancer unit. All patients were treated in the Holycross Cancer Centre in Kielce (in 2015–2018). 
Results. The early results show that proper qualification and realisation of oncological treatment is safe and effective. 
Severe complications appeared rarely.
Conclusions. Skin-sparing or nipple-sparing mastectomy is a method of surgical treatment that is increasingly used in 
the treatment of patients with breast cancer. It should be remembered that the qualification for this type of procedure 
should be careful, and adjuvant treatment should be rationally planned. Our experience shows that it is an effective and 
safe method.
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Introduction
In the last decade, both nipple-sparing mastectomy (NSM) and 
skin-sparing mastectomy (SSM) with immediate reconstruction 
with a prosthesis or expander have been used in the surgical ma-
nagement of non-metastatic breast cancer patients, although 
their oncologic safety has not been established in randomised 
controlled trials. The literature pointed that the outcomes of the 
treatment with NSM, SSM and modified radical mastectomy 
(MRM) are similar, but, importantly, subcutaneous mastectomies 
preserve the patient’s body  shape [1–4]. NSM or SSM can be 
connected with sentinel lymph node biopsy in patients with 
clinically negative lymph nodes. In literature, data is limited 
about proceeding with patients after NSM or SSM with a posi-
tive sentinel lymph node. In our paper, we present the clinical 
implications of the treatment of women after NSM or SSM and 
the sentinel lymph node biopsy procedure. 
Material and methods
Between 2015–2018, 290 women with NSM or SSM were 
treated in the Holycross Cancer Centre in Kielce. The group of 
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62 previously untreated women with positive sentinel lymph 
nodes took part in this analysis. An individual plan of treatment 
was established for every patient by the multidisciplinary team 
according to the rules of the breast cancer unit. Statistical 
analyses were performed using MedCalc Statistical Software 
ver. 19.6 (MedCalc Software bv, Ostend, Belgium; https://www.
medcalc.org; 2020). Basic statistical measures for continuous 
variables, as well as frequencies and percentages for qualitative 
and ordinal variables were calculated. The Chi-square test was 
used to assess the interdependence of variables in double 
classifications and the T-Student or Mann-Whitney test for 
continuous variables to examine the differentiation of the two 
groups studied were applied. It was assumed that p values less 
than 0.05 indicate statistical significance.
Results
The analysed group consisted of 62 women. The mean time of 
observation was 46 months (min.: 11months, max.:72 months). 
The mean age of women was 49 years old. NSM and SSM were 
performed in 48 and 14 patients, respectively.
The surgical margins in all patients were negative. In 60 
patients, cancer was diagnosed in the I and II clinical stages, 
in 2 patients in the III stages. The non-special type of cancer 
prevailed (51 patients). Luminal subtypes were recognised in 
42 patients, both, HER2-positive and triple-negative subtypes 
in 7. In the analysed group, positive sentinel nodes were found 
in all patients. In 30 of them, an extracapsular extension (ECE) in 
the sentinel lymph node was diagnosed. In the group with ECE, 
axillary dissection (AD) was performed in 15 patients. Patients 
with massive extracapsular extension and a high ratio between 
occupied to removed sentinel lymph nodes were qualified to 
AD. The decision about performing AD was also taken multidi-
sciplinary. In 8 patients after AD, additional lymph nodes with 
metastases were found, but the pathological nodes (pN) and 
stage (pN1 to pN2 or pN3) changed only in 5 women. In the 
group without ECE in sentinel lymph nodes, only 1 patient had 
axillary dissection performed. Chemotherapy, hormonothe-
rapy and anti-HER2 therapy were implemented according to 
indications. Statistically, chemotherapy was applied in patients 
with ECE more often. The most common regimen of chemo-
therapy was 4 cycles of adriamycin and cyclophosphamid 
followed by 12 cycles of paclitaxel – applied to  28 patients. 
Postoperative conformal radiotherapy (PORT) was applied in 
58 out of 62 patients (fig. 1). 
Three patients refused radiotherapy. In one female patient 
micro-metastases to the sentinel lymph node were recognised. 
In patients with positive 1–3 macro-metastatic sentinel lymph 
nodes without ECE radiotherapy replaced axillary dissection. 
In the group with ECE for patients after SLNB and AD, radio-
therapy was also applied. In patients with 1–3 positive lymph 
nodes we included various factors to deliver postoperative 
radiotherapy: 
• age below 50, 
• tumour diameter, 
• high grading, 
• lymphovascular or perineural invasion, 
• Ki-67 factor, 
• triple-negative or HER2 positive subtypes. 
Local recurrence was not diagnosed in the analysed pa-
tients. In our group, two patients died due to the spread of the 
cancer. In both, triple-negative breast cancer was recognised 
and they were 28 and 37 years old, respectively. Sixty patients 
survived. 
Figure 1. Patients after NSM and radiotherapy
Table I. Characteristics of the analyzed group
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with positive sentinel nodes undergoing breast-conserving 
treatment, axillary lymphadenectomy can be abandoned in 
the case of irradiation of the axilla. 
The problem can be seen similarly in patients after a sub-
cutaneous mastectomy and sentinel node biopsy. In our group, 
we did not perform a lymphadenectomy in patients with no 
extracapsular infiltration – apart from one woman. What re-
mains important is that in almost half of patients undergoing 
axillary dissection, additional metastatic lymph nodes were 
not found. Literature shows that surgery should be limited 
in the axilla region and rationally replaced by radiotherapy 
[18–20]. We must remember that PORT should be realised with 
conformal techniques, and the preparation of patients should 
be made after international consensus and recommendations 
[21–22]. Complications after PORT are frequent. It is associated 
with the formation of a fibrous capsule or damage of the pro-
sthesis. In our group, complications occurred in 9 patients and 
frequency was similar to that in the cited literature. Damage 
of the prosthesis was associated with its replacement [23–26]. 
Conclusions
A skin-sparing or nipple-sparing mastectomy is a method of 
surgical treatment that is increasingly used in the treatment 
of patients with breast cancer. More often women themselves 
decide or even ask to undergo this type of surgery. It should 
be remembered that qualification of patients for this type of 
procedure should be cautious, and adjuvant treatment should 
be rationally planned. Our experience shows that it is an effec-
tive and safe method. Randomised trials with the recruitment 
of patients are also necessary to assess its effectiveness as well 
as the potential complications arising after this type of surgery 
with the usage of additional methods.
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